According to the Berlin-based contract research organization (CRO), the new consulting service is aimed at biotechnology companies as well as small and medium pharmaceutical companies.
"There is a number of consulting firms providing service to biotech companies, there is clearly a demand," said Mike Jagielski, CEO of KCR.
"At KCR we saw the consulting demand increase substantially over the last two years, leading to the decision to create a separate service area," he told Outsourcing-Pharma.com.
Jagielski said the new offering will allow the company to focus on consulting independent from its trial execution services.
The service covers three main areas, including study design and clinical development, regulatory affairs, and study execution, he explained.
The CRO has four hubs located in Berlin, Germany; Warsaw, Poland; Kiev, Ukraine; and Boston, MA, the company’s US office that opened in June last year.